Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study

Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study

To date, there are no specific therapeutic strategies for treatment of COVID-19. Based on the hypothesis that complement and coagulation cascades are activated by viral infection, and might trigger an acute respiratory distress syndrome (ARDS), we report clinical outcomes of 17 consecutive cases of...

Full description

Bibliographic Details
Main Authors: Valentina Giudice, Pasquale Pagliano, Alessandro Vatrella, Alfonso Masullo, Sergio Poto, Benedetto Maria Polverino, Renato Gammaldi, Angelantonio Maglio, Carmine Sellitto, Carolina Vitale, Bianca Serio, Bianca Cuffa, Anna Borrelli, Carmine Vecchione, Amelia Filippelli, Carmine Selleri
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-06-01
Series:Frontiers in Pharmacology
Subjects:
JAK inhibitor
eculizumab
ARDS (acute respiratory distress syndrome)
COVID-19
SARS-CoV-2
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.00857/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2020.00857/full

Similar Items